Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 31Lymphoid 22Myeloid 18Sarcoma 10Plasma cell 10Dermatologic 6CNS 5Other solid neoplasm 4Genitourinary 4Gastrointestinal 4Classical hematology 4Breast 3Other neoplasm 2Head & Neck 2Tumor-Agnostic 1Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sirolimus × Thoracic × 1 year × Clear all
NCT01737502 2025-09-05

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Mayo Clinic

Phase 1/2 Completed
29 enrolled 16 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡